Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EPS (Basic): 2013-2025

Historic EPS (Basic) for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to -$0.38.

  • Coherus Oncology's EPS (Basic) rose 7.32% to -$0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.43, marking a year-over-year increase of 576.39%. This contributed to the annual value of $0.25 for FY2024, which is 109.88% up from last year.
  • As of Q3 2025, Coherus Oncology's EPS (Basic) stood at -$0.38, which was down 114.79% from $2.57 recorded in Q2 2025.
  • Coherus Oncology's EPS (Basic)'s 5-year high stood at $2.57 during Q2 2025, with a 5-year trough of -$2.37 in Q1 2021.
  • For the 3-year period, Coherus Oncology's EPS (Basic) averaged around $0.08, with its median value being -$0.41 (2024).
  • As far as peak fluctuations go, Coherus Oncology's EPS (Basic) crashed by 574.00% in 2021, and later soared by 635.42% in 2025.
  • Coherus Oncology's EPS (Basic) (Quarterly) stood at -$0.59 in 2021, then fell by 28.81% to -$0.76 in 2022, then climbed by 2.63% to -$0.74 in 2023, then soared by 333.78% to $1.73 in 2024, then grew by 7.32% to -$0.38 in 2025.
  • Its EPS (Basic) stands at -$0.38 for Q3 2025, versus $2.57 for Q2 2025 and -$0.49 for Q1 2025.